Indications for: APONVIE

Prevention of postoperative nausea and vomiting (PONV).

Limitations of Use:

Not for treating established nausea and vomiting.

Adult Dosage:

Give prior to induction of anesthesia.  32mg IV over 30secs. Flush with normal saline prior to and after administration. 

Children Dosage:

Not established.

APONVIE Contraindications:

Concomitant pimozide. 

APONVIE Warnings/Precautions:

Monitor for hypersensitivity reactions; discontinue and treat appropriately if occur; do not reinitiate if symptoms developed with previous use. Severe hepatic impairment. Pregnancy: avoid. Advise females of reproductive potential using hormonal contraceptives to use an effective alternative or back-up non-hormonal contraception for 1 month after administration. Nursing mothers.

APONVIE Classification:

Substance P/NK1 receptor antagonist.

APONVIE Interactions:

See Contraindications. Avoid concomitant strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) or strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin). May antagonize warfarin (closely monitor INR for 2 weeks after starting each cycle), other CYP2C9 substrates, oral contraceptives (use alternative or backup methods [eg, condoms, spermicides]).

Adverse Reactions:

Constipation, fatigue, headache.


Hepatic (primarily CYP3A4), (minor CYP1A2, CYP2C19). 

Drug Elimination:

Half-life: 12 hours. Mean plasma clearance: 4.4 L/h.

Generic Drug Availability:


How Supplied:

Single-dose vials—10